Rheumatoid Arthritis

Test your knowledge of the treatment and management of rheumatoid arthritis (RA) with our RA quizzes.

Looking specifically at patients who have been treated with biologic disease-modifying anti-rheumatic drugs, this study examines the risk of new or recurrent cancer.

Catch up on Rheumatology Network's most recent highlights in rheumatoid arthritis news.

“In patients with rheumatoid arthritis, the prevalence of depression ranges between 14.8 and 22.5%, which is 2 to 3 times higher than in the general population,” investigators stated.

While the antioxidants in tea may reduce the risk of developing inflammatory diseases, such as rheumatoid arthritis, previous studies have shown inconclusive results.

While lifestyle habits are modifiable risk factors, changing them can be especially challenging for patients with rheumatoid arthritis, who must also deal with chronic inflammatory disease.

Effective treatment for patients with moderate-to-severe rheumatoid arthritis can control symptoms quickly and slow disease progression. How should such patients be managed? Test your knowledge with this quiz.

“The COVID-19 pandemic has strongly impacted the lives of patients living with rheumatoid arthritis which has contributed to anxiety, depression, and reduced well-being.”

Most patients share a fear of falling or psychological distress that can exacerbate physical limitations. In fact, more than half of RA patients report significant fear of falling.

The survey found that 22.3% (n = 62) patients reduced or interrupted treatment and only 3.9% (n = 11) patients stopped treatment entirely. The duration of disease (p = 0.023) and disease activity (p = 0.001) were significant contributing factors in the decision to discontinue treatment.

The move comes amid delays in FDA approvals for multiple JAK inhibitors for the treatment of rheumatic conditions.

Booster doses of the COVID-19 vaccine are recommended for many patients with rheumatoid arthritis. Test your knowledge on who is eligible for a booster and how it should be administered with this quiz.

How much do you know about the treatment of patients with rheumatoid arthritis? Find out now with our quiz.

Test your knowledge with our Rheumatoid Arthritis: 2021 Highlights quiz!

Investigators gathered data from vulnerable populations with rheumatic disease regarding their thoughts and opinions on the COVID-19 virus.

In this retrospective study, investigators analyzed patients with newly diagnosed RA, to determine if short-term, low doses (< 10 mg/day) of prednisone would help DAS28-ESR score.

Daniel Hernandez, MD, and Esteban Rivera discuss the study, “Social Listening: Factual vs. Misinformation YouTube Spanish-Language Rheumatoid Arthritis Videos,” presented at the 23rd Pan-American Conference of Rheumatology (PANLAR) 2021.

Bryant England, MD, discusses his presentation entitled, “Epidemiology of Multimorbidity in Rheumatoid Arthritis."

Test your knowledge of rheumatoid arthritis with our "Best of 2020" quiz!

John Cush, MD, discusses his upcoming lecture entitled, “Rheumatoid Arthritis: Year in Review,” which will be presented at the Congress of Clinical Rheumatology.

On this month's episode of Overdrive, Roy Fleischmann, MD, discusses the recent Pfizer press release regarding the safety of JAK inhibitors and his personal opinions on prescribing JAK inhibiting drugs to his patients.

After controlling for variables, eldery-onset rheumatoid arthritis (EORA) was not indicative of changes in Clinical Disease Activity Index (CDAI) scores over time when compared with a non-EORA cohort. Further, there were no significant differences in the efficacy and safety of receiving biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).

While prevention of atherosclerotic cardiovascular disease (ASCVD) in patients with rheumatoid arthritis (RA) is advocated by recent recommendations, ASCVD prevention in patients with RA was underwhelming, according to an international audit.

Roy Fleischmann, MD, discusses the recent Pfizer press release touching upon the safety of JAK inhibitors. He explains the recent scrutiny of JAKs, the concerns some rheumatologists have in regard to JAK inhibitors, and his personal opinions on prescribing JAK inhibiting drugs to his patients.